Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × evolocumab × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Endocrine 1 CNS 1

Conditions

Multiple Endocrine Neoplasia Type 1 1 Coronary Disease 1

Interventions

Everolimus 28 Octreotide 13 Cisplatin 12 Sunitinib 10 Etoposide 9 pasireotide 8 Temozolomide 8 Doxorubicin 8 Bevacizumab 8 pembrolizumab 7 lutetium Lu 177 dotatate 7 lanreotide 7 3-Iodobenzylguanidine 7 gallium Ga 68 dotatate 6 Positron Emission Tomography Computed Tomography 6 Paclitaxel 6 Magnetic Resonance Spectroscopy 6 pazopanib 5 lenvatinib 5 Surgical Procedures, Operative 5 Radiotherapy 5 Irinotecan 5 Fulvestrant 5 Capecitabine 5 surufatinib 4 avelumab 4 Sorafenib 4 Radiosurgery 4 Mitotane 4 Iodine-131 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03872401 2025-11-10

VESALIUS-CV

Amgen

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡